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Abstract
The IgM Fc receptor (FcμR), originally cloned as “Fas-apoptosis inhibitory molecule (FAIM3/
TOSO)” can function as a cell surface receptor for secreted IgM on a variety of cell types. We 
report that FcμR also is expressed in the trans-Golgi network of developing B cells, where it 
constrains IgM- but not IgD-BCR transport. In FcμR absence, IgM-BCR surface expression was 
increased, resulting in enhanced tonic BCR signaling. B cell-specific FcμR-deficiency enhanced 
spontaneous differentiation of B-1 cells, resulting in increases in natural IgM levels, and 
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dysregulated B-2 cell homeostasis, causing spontaneous germinal center formation, increased 
serum autoantibody titers, and excessive B cell accumulation. Thus, FcμR/FAIM3 is a critical 
regulator of B cell biology by constraining IgM-BCR transport and cell surface expression.
Introduction
The Fc-receptor for IgM (FcμR) is a transmembrane receptor that was initially named Fas 
apoptosis inhibitory molecule 3 (FAIM3 or TOSO), because transfection experiments 
indicated this protein protected Jurkat T cells from Fas-induced programmed cell death in 
vitro1, 2, 3. More recently, however, several studies identified FAIM3 as the long elusive Fc-
receptor for IgM that is expressed on the cell surface of human and mouse primary follicular 
B cells. Those studies failed to find evidence for a Fas-inhibitory activity on these cells4, 5. 
They therefore renamed the molecule “FcμR”. Others since confirmed the IgM-binding 
activity of this receptor6, 7, 8.
FcμR surface expression was reported for various leukocyte populations, including 
granulocytes, macrophages, monocytes, dendritic cells, and regulatory T cells. The highest 
expressions were noted in B cells8, 9, 10. Studies with global FcμR-deficient mice suggested 
that the receptor broadly regulates cellular activation, such as inflammatory responses of 
dendritic cells and regulatory T cells in autoimmune diseases10, the maturation and 
differentiation of dendritic cells in lymphocytic choriomeningitis virus infection11, and the 
production of reactive oxygen species of neutrophils9. Global FcμR-deficient mice also 
showed increases in serum IgG autoantibody titers, as well as increased concentrations of 
natural serum IgM6, 7. The mechanism by which FcμR regulates B cell homeostasis and 
autoantibody production has not been elucidated.
Recent confocal imaging suggested that the FcμR might also interact with the membrane-
bound IgM (mIgM)-BCR on the B cell surface, where these molecules co-localize12. The 
mIgM-BCR consists of mIgM and associated signaling chains CD79a and CD79b. IgM 
undergoes extensive posttranslational modifications and is sorted in the trans-Golgi network 
(TGN) for transport to the cell surface13. The BCR provides constitutive, low-levels “tonic” 
signals, required for B cell survival14. During bone marrow (BM) development, mIgM-BCR 
signaling regulates B cell selection. Once B cells are mature, antigen encounter by the BCR 
induces B cell activation and differentiation15.
In humans, dysregulated expression of the FcμR has been associated with various B cell 
malignancies16, 17. On CLL cells and transiently transfected HeLa cells the FcμR 
internalized soluble IgM and transported it from the cell surface to the lysosome for 
degradation, suggesting it may uptake IgM-antigen complexes. In transfected HeLa cells 
localization of the FcμR was detected not only on the cell surface and following 
internalization in the lysosomes, but also in the trans-Golgi network (TGN)16. Thus 
indicating that mIgM-FcμR interaction could occur in the TGN also during development of 
B cells.
Indeed, using high resolution microscopy and proximal ligation assays we demonstrate that 
the FcμR interacts directly with mIgM in the TGN of immature B cells and that this 
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interaction regulates BCR surface expression and thereby tonic BCR signaling. The lack of 
FcμR-mediated suppression of BCR-surface expression, and therefore signaling, in B cells 
of tissue-specific FcμR-deficient mice (Fcmr flx/flxCd19-Cre), resulted in dysregulated 
spontaneous activation and differentiation of B-1 and B-2 cells and development of a 
lymphoproliferative disorder. Our data support a model whereby the FcμR constrains BCR 
expression to regulate fundamental B cell homeostasis and biology.
RESULTS
FcμR surface expression is highest on B cells
Consistent with prior reports4, 7, 8, 18, the highest surface expression of the FcμR was seen 
on B cells, but mostly absent on CD4 and CD8 T cells (Supplementary Fig. 1a,b). Myeloid 
cell populations, such as Gr-1+ (granulocytes), CD11b+/F4/80+ (macrophages) and CD11c+ 
(dendritic cells) showed low surface expressions (Supplementary Fig. 1a,b). mRNA 
expression analysis confirmed Fcmr expression by all peripheral B cell subsets. It was 
highest in splenic follicular (FO) B cells (CD19+IgDhiCD23+) and splenic B-1 cells 
(CD19hiIgMhiIgDloCD23−CD43+), and somewhat lower in marginal zone (MZ) B cells 
(CD19+CD21hiCD23−) and in peritoneal cavity B-1 cells (Fig. 1a). Protein expression 
analysis confirmed high surface expression by splenic B-1 cells but also by MZ B cells. 
Surface expression of the FcμR appeared low in the peritoneal cavity (Figure. 1b and 
Supplementary Fig. 1c). Splenic FO B cells showed higher FcμR expression compared to 
FO B cells in inguinal lymph nodes (Figure. 1b and Supplementary Fig. 1c). Thus, the FcμR 
is dynamically regulated in various B cell subsets and by tissue location.
During BM development, FcμR expression was seen first at the late pre-B cell stage, with 
rapidly increasing expression among immature B cells (Fig. 1c,d and Supplementary Fig. 
1d). Confocal microscopy confirmed expression of the FcμR on the surface of 
B220+CD43−IgMlo/+IgD− immature B cells (Fig. 1e). But we also noted an unexpected 
strong intracellular presence of the FcμR. Two-color confocal microscopy of primary 
immature B cells localized the FcμR to the trans-Golgi network (TGN), using the marker 
TGN-38 (Fig. 1e). The TGN plays a central role in post-translational modifications and the 
sorting of mIgM for transport13, 19. This suggested that the FcμR may interact with mIgM 
during B cell development, when IgM is modified and first transported to the cell surface. 
Together, the data demonstrate correlated expression of the FcμR and mIgM during the 
transition from the late pre-B to the immature B cell stage. In developing B cells the FcμR 
receptor is present in two distinct compartments that include the cell membrane and the 
TGN.
The FcμR interacts with secreted and membrane IgM
To study the direct effects of IgM-FcμR interaction in B cells, we created B cell-specific 
Fcmr−/− mice using the Cre-lox system, with Cre expression driven by the Cd19 promoter. 
For most experiments the Fcmr flx/flxCd19-Cre+ mice were compared to littermate Fcmr
flx/flxCd19-Cre− controls. Flow cytometry (Supplementary Fig. 1a) and gene expression 
analysis (Fig. 1f) on flow cytometry-sorted splenic B cells confirmed the B cell-specific 
deletion of the Fcmr.
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Despite expression of the FcμR early in B cell development, Fcmr flx/flxCd19-Cre+ mice 
showed no overt defects in B cell development. All B cell developmental stages were present 
at frequencies and numbers comparable to their controls (Supplementary Fig. 2a). 
Furthermore, there was no difference in the rate at which the receptor-deficient mice 
accumulated immature CD93+ B cells in the spleen 12 days after sublethal irradiation 
(Supplementary Fig. 2b,c).
As we and others showed previously4, 16, 20, secreted IgM (sIgM) can bind to the cell 
surface of B cells. As expected, genetic ablation of the FcμR reduced sIgM binding to B 
cells in vitro (Fig. 2a and Supplementary Fig. 3a), which we tested by exposing purified 
spleen B cells from controls and Fcmr flx/flxCd19-Cre+ mice to purified and biotinylated 
sIgM. Surface sIgM binding was rapidly lost, independent of the B cell source 
(Supplementary Fig. 3a,b), suggesting rapid internalization. T cells did not bind to sIgM 
(Supplementary 3b). To determine whether similar binding of sIgM to B cells occurs in vivo, 
and if so, what effects removal of the FcμR may have on that binding, we adoptively 
transferred control or Fcmr flx/flxCd19-Cre+ IgHb-expressing B cells into congenic IgHa-
expressing mice. 72 h after transfer the amount of secreted IgM (IgMa) binding to the 
surface of wild-type and Fcmr−/− B cells was compared by flow cytometry, identifying the 
transferred cells via IgDb (Fig. 2b). The CD19+IgDb Fcmr−/− B cells bound significantly less 
sIgMa compared to B cells from controls, as indicated by reduced MFI for IgMa staining 
(Fig. 2b–c), In vivo bound sIgM was lost as rapidly in culture as after incubation with sIgM 
in vivo (Supplementary Fig. 3c). In contrast, and unexpectedly, the Fcmr−/− B cells stained 
more strongly for the mIgM-BCR (IgHb) compared to their controls (Fig. 2c–d). Thus, the 
FcμR facilitates the in vivo binding of natural IgM to the surface of B cells and appears to be 
involved also in IgM-BCR surface expression.
Immunoprecipitation studies demonstrated that the FcμR can directly bind to and interact 
with IgM4, 12. To distinguish FcμR interaction with the membrane and secreted form of IgM, 
respectively, we first conducted stimulated emission depletion (STED) microscopy, which 
provides resolution of two proteins down to 50nm in living cells21. To differentiate between 
mIgM and sIgM we isolated B cells from mixed BM irradiation chimeras, which were 
generated by adaptive transfer of BM from wild-type (IgHb) and μs−/− (IgHa) mice into 
lethally irradiated recipients. B cells from μs−/− mice lack the μs exon, encoding the secreted 
form of IgM, but they express mIgM22. In these chimeras, all sIgM is therefore derived from 
the IgHb expressing wild-type B cells. Staining for IgD with allotype-specific mAb 
determined the Ig-genotype of follicular (FO) B cells, such that analysis of IgDa-expressing 
μs−/− cells distinguished mIgM (IgMa) expression from sIgM (IgMb) –binding directly ex 
vivo. The exquisite specificity of the monoclonal antibodies anti-IgMa (DS.1) and anti-IgMb 
(AF6.78.25) is well known23, 24, 25 and was further demonstrated by us (Supplementary Fig. 
4a–c). Analysis of FO B cells revealed that mIgMa was expressed evenly on the cell surface, 
whereas sIgMb was more focally spaced (Fig. 2e). Secreted- but not mIgM was also seen in 
vesicles directly beneath the cell membrane (Fig. 2e,f), consistent with the previously 
reported internalization of sIgM into endosomes16. Direct ex-vivo visualization of sIgM-
internalization by splenic FO B cells suggested that this is an ongoing process. FO B cells 
lacked measurable mIgM in intracellular compartments (Fig. 2e,f), likely due to low 
turnover rates of mIgM26.
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Next we used three-color confocal microscopy on FO B cells from the same mice to study 
co-localization of the FcμR with mIgM and/or sIgM. On the cell membrane the FcμR co-
localized with both, mIgM and sIgM (Fig. 2f, arrows indicate co-localization), while there 
was little if any co-localization in the TGN, (Supplementary Fig. 5a). In contrast, STED 
microscopy of immature B cells showed that the FcμR co-localized with IgM both on the 
cell membrane as well as in the TGN (Fig. 2g,h and Supplementary Fig. 5b). The 
intracellular co-localization was strongly focal/vesicular, with individual vesicles containing 
both FcμR and IgM in close proximity to the cell membrane, suggesting transport 
(Supplementary Fig. 5b).
To provide further evidence of FcμR and mIgM interaction, we used the Fab-based 
Proximity Ligation Assay (Fab-PLA) with a 10–20 nm resolution capacity27. Strong Fab-
PLA signals (depicted in red), indicative of protein-protein interaction, were detected in the 
cytosol of saponin-treated B220+CD43−CD25−IgD− immature BM B cells at a subcellular 
region that stained with the Golgi-marker lectin-GSII-Alexa 488 (Fig. 2i-top and 
Supplementary Fig. 5c). The FcμR-mIgM interaction occurred also on the cell surface 
(stained for GM-1 with the cholera toxin subunit B-FITC) of intact immature B cells, albeit 
to a lesser extent (Fig. 2i-bottom). In contrast, the splenic mature FO B cells displayed only 
weak FcμR-mIgM interactions and only on the cell surface (Fig. 2j-compare top to bottom 
and Supplementary Fig. 5c). Together the studies revealed strong interactions of the FcμR 
with IgM in the TGN of immature B cells, and much weaker interactions on the cell surface 
of mature B cells.
FcμR-mIgM interaction constrains BCR surface expression
The TGN of primary B cells contains mIgM but not sIgM16, 19, thus the FcμR could affect 
mIgM transport. Flow cytometry on B cells from Fcmr flx/flxCd19-Cre and wild type mice 
showed similar staining for total surface IgM (Fig. 3a). However, separate staining for sIgM-
binding and mIgM expression after transfer of either control or Fcmr flx/flxCd19-Cre B cells 
(IgHb) to (IgHa) mice, revealed that increased expression of mIgM by the Fcmr−/− B cells 
was offset by reduced surface binding of sIgM, masking differences in IgM-BCR 
expression. This was confirmed by the transfer of FO B cells from either Fcmr flx/flxCd19-
Cre or control mice into B cell-deficient mice. While staining for total (secreted plus 
membrane-bound) IgM was similar prior to transfer (Fig. 3a), 72h after transfer increased 
surface IgM staining was seen on B cells from Fcmr flx/flxCd19-Cre mice compared to 
controls, presumably because the bound sIgM was internalized, leaving only surface mIgM 
(Fig. 3b). Consistent with this, Igα (CD79a) expression was significantly increased in the 
Fcmr –deficient B cells compared to controls (Fig. 3c). Increased mIgM expression by Fcmr 
–deficient B cells was not due to alterations in gene transcription (Fig. 3d). The data 
suggested that the interaction with the FcμR in the TGN of developing immature B cells 
constrains the transport of mIgM, and/or its retention on the cell surface.
To provide evidence of FcμR-mediated mIgM transport regulation, we expressed chimeric 
GFP-μm (IgM) heavy chains (HC) either alone, or as chimeric IgM-BCR together with the 
signaling subunits CD79a and CD79b (Fig. 3e) in a S2 Drosophila cell system28. As 
expected, only a fully assembled IgM-BCR was placed on the cell surface and its amount 
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was significantly reduced after co-expression of the FcμR (Fig. 3f,g). IgD-BCR expression 
was not altered, when co-expressed with the FcμR either in different or in the same cell (Fig. 
3f,g). To determine whether FcμR affects IgM-BCR transport, we measured the re-
appearance of IgM-BCR GFP-fluorescence after photobleaching (FRAP) on the surface of 
transfected S2 cells (Fig. 3h,i). The mobile fraction (Mf) and the half-time recovery data 
showed that the reappearance of IgM-BCR fluorescence, was significantly reduced in the 
presence of the FcμR, while IgD-BCR expression was not affected. (Fig. 3h,i). We conclude 
that the FcμR directly and specifically restricts transport of the IgM-BCR to the surface of 
developing B cells.
Enhanced tonic BCR signaling in Fcmr−/− B cells
Surface BCR expression is required for B cell survival, and the amount of surface BCR 
influences both B cell development and mature B cell reactivity. Therefore, we determined 
next whether increased mIgM-BCR surface expressions by Fcmr−/− B cells affected steady 
state or “tonic” BCR signaling. Tonic BCR signaling triggers phosphorylation of 
phosphoinositide 3-kinase (PI3K) and its down-stream targets, including Erk, Ras and 
Akt29, 30. The transcriptional repressor Foxo1 is a major target of phosphorylated Akt (pAkt, 
Ser473) in tonic BCR signaling29. De-repression of the Foxo1 target Cdkn1b can lead to cell 
cycle entry of FO B cells29, 31. Foxo1 also controls cell survival, in part via repression of the 
cellular stress sensor and pro-apoptotic gene Bcl2l1129, 32.
Expression of the regulatory (p85) as well as the catalytic (p110) subunit33 of PI3K were 
significantly increased in B cells from Fcmr flx/flxCd19-Cre mice compared to controls (Fig. 
4a,b), as was pAkt in purified B-2 and in B-1 cells (Fig. 4c,d). B-1 cells expressed more 
pAkt compared to B-2 cells in control and Fcmr flx/flxCd19-Cre mice (Fig. 4d). Heightened 
tonic BCR signaling of B-1 cells is consistent with their increased auto-reactive 
repertoire34, 35. Phosphorylated Btk (pBtk) was also increased in freshly isolated Fcmr−/− 
B-1 and B-2 cells (Fig. 4e,f) and increased pAkt and pBtk were seen in Fcmr−/− B cells 
derived from chimeras established with BM from global Fcmr−/− compared to control 
chimeras (Supplementary Fig. 6a,b). Cre-toxicity was not responsible for phosphorylation 
differences, as increased PI3K/pAkt were only observed in Fcmr flx/flxCd19-Cre mice and 
not in Fcmr wt/flxCd19-Cre, Fcmr wt/flxCd19-Cre− mice, or Fcmr flx/flxCd19-Cre− mice 
(Supplementary Fig. 7a,b). A good correlation existed between the expressions of pAkt and 
pBtk expressed by B cells and surface expressions of IgM (Fig. 4g and data not shown). This 
correlation was stronger in B cells from Fcmr flx/flxCd19-Cre mice than in controls, 
presumably because IgM staining is labeling the BCR only, while in wild-type B cells it 
labels both mIgM and sIgM; the latter not likely affecting BCR signaling. The data suggest 
that the stronger signaling in Fcmr −/− B cells is the direct outcome of enhanced mIgM 
expression.
Assessment of mRNA expression of three Foxo1 target genes showed expected changes in 
Fcmr flx/flxCd19-Cre B cells compared to controls, all indicative of enhanced tonic BCR 
signaling. The cell cycle inhibitor Cdkn1b (P27) and the pro-apoptotic Bcl-2 family member 
Bcl2l11 were significantly reduced in the absence of FcμR, while Aicda, a gene upregulated 
by Foxo1 activation was significantly increased (Fig. 4h). Rag1 was not expressed in B cells 
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from either control or Fcmr flx/flxCd19-Cre mice (Fig. 4h). The data indicate that the FcμR 
regulates tonic BCR signaling by constraining surface expression of mIgM during B cell 
development.
To determine whether the absence of the FcμR affected B cell response to BCR crosslinking, 
we compared the responses of purified FO B cells from control and Fcmr flx/flxCd19-Cre 
mice to anti-IgM stimulation. Both, pAkt expression and B cell proliferation were 
comparable in these cultures (Fig. 4i–j). However, consistent with the ex vivo results, the 
Fcmr−/− B cells expressed more pAkt in the absence of stimulation after culture, compared 
to control B cells (Fig. 4j). Consistent with the reduced expression of the pro-apoptotic 
regulator Bcl2l11, in vitro cultures of Fcmr−/− B-1 and B-2 cells showed increased cell 
survival (Fig. 4k,l). This survival advantage was lost after stimulation with anti-IgM, anti-
IgM plus anti-Fas, and lipopolysaccharide (Fig. 4k,l). Thus, the absence of the FcμR and 
resulting increases in BCR expression, enhanced tonic BCR signaling and B cell survival, 
while not significantly affecting signaling after strong anti-IgM mediated BCR cross-
linking.
FcμR regulates natural IgM and autoantibody production
Increased BCR expression and resulting increases in tonic BCR signaling are expected to 
affect B cell homeostasis. Indeed, serum sIgM concentrations in Fcmr flx/flxCd19-Cre mice 
were twice that of their controls (Fig. 5a), similar to those reported for global Fcmr−/− 
mice6, 7, while IgA concentrations were comparable and IgG concentrations were 
consistently, but not significantly, increased (Fig. 5b,c). Explaining the increases in serum 
IgM concentrations, frequencies of IgM secreting cells in spleen and BM were also greatly 
increased in Fcmr flx/flxCd19-Cre mice (Fig. 5d). In addition, IgM spot sizes appeared bigger 
than those of controls (Fig. 5d). Frequencies of spontaneous IgG secreting cells were also 
increased (Fig. 5e), and anti-dsDNA IgM and IgG titers were significantly elevated (Fig. 
5f,g) in Fcmr flx/flxCd19-Cre mice, as seen also in global Fcmr−/− mice7, 8. However, after 
normalization of autoantibody concentrations to total Ig concentrations, the relative amounts 
of IgM anti-dsDNA were reduced rather then enhanced (Fig. 5f), while the relative amounts 
of anti-dsDNA IgG remained elevated (Fig. 5g). Together, the data demonstrate that direct 
FcμR signaling suppresses the development of natural IgM and of IgG autoantibody-
producing cells in a B cell-intrinsic manner.
The FcμR was shown to inhibit Fas–FasL-mediated apoptosis in transfected T cell lines3. We 
found that Fas-induced cell death in vitro was only measurable in cultures of Fcmr−/− B-1 
and FO B cells, but not in controls. This apparent inhibitory effect of the FcμR on Fas-
mediated killing directly correlated with higher frequencies and absolute numbers of Fas-
expressing CD38lowPNA+ germinal center B cells in the spleens of Fcmrflx/flxCd19-Cre 
mice (Fig. 5h,i). Importantly, the observed increases in tonic BCR signaling seem to lead to 
increased spontaneous B cell activation and germinal center formation, a likely source of the 
increased auto-reactive serum IgG titers (Fig. 5g). The apparent protection from Fas-induced 
cell death in the presence of the FcμR observable in vitro thus appears to be due mainly to 
the suppression of spontaneous B cell activation and therefore reduced Fas-expression. This 
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is further supported by the fact that Fas-induced cell death in vitro only reduced the 
frequencies of Fcmr−/− B cell survival to frequencies seen in control B cell cultures.
Natural IgM is important for early immune protection against bacteria and viruses such as 
influenza24, 36, 37. Consistent with elevated baseline concentrations of total serum IgM, 
concentrations of natural IgM that binds influenza A/Puerto Rico 8/34 (A/PR8) were 
significantly elevated in infection-naïve Fcmr flx/flxCd19-Cre mice compared to controls. 
The increased natural IgM levels before (Fig. 5j), and at day 1 after infection with A/PR8 
(Fig. 5k,l), correlated with increased early control of lung influenza viral loads (Fig. 5m). 
We conclude that the FcμR expression in B cells reduces protective natural IgM serum 
levels, but also controls potentially harmful auto-reactive IgG.
Enhanced B-1 activation in Fcmr flx/flxCd19-Cre mice
Increased BCR signaling leads to enhanced B-1 cell development, a cell population largely 
responsible for natural IgM production35. As expected from the increased serum IgM 
concentrations, Fcmr flx/flxCd19-Cre mice showed strong increases in the frequencies and 
numbers of splenic B-1 cells, particularly CD5+ B-1a cells (Fig. 6a and Supplementary Fig. 
7c), while their relative and absolute numbers in the peritoneal cavity were normal (Fig. 6b, 
Supplementary Fig. 7d). BM B-1 cell numbers were also higher, although this did not reach 
statistical significance (Fig. 6c). Controls, including Fcmr flx/flxCd19-Cre-, Fcmr wt/flxCd19-
Cre- and Fcmr wt/flxCd19-Cre+ had B-1 cell populations similar to those of wild-type mice 
(Supplementary Fig. 7c). We conclude that the FcμR regulates B-1 cell activation and 
natural IgM secretion by regulating BCR-expression.
To determine whether Fcmr−/− B-1 cells are responsible for the increased IgM production in 
Fcmr flx/flxCd19-Cre mice, we generated neonatal Ig-allotype chimeras, in which only B-1 
cells (IgHb) lacked expression of the Fcmr−/−, while all BM-derived B cells were wild-type 
(IgHa). Control chimeras were reconstituted with Fcmr flx/flxCd19-Cre− peritoneal cavity 
cells (IgHb). Frequencies of Fcmr−/− B-1 cells (IgMb) in the peritoneal cavity were 
comparable to chimeras generated with control B-1 cells, but were at least double that in 
spleen and BM (Fig. 6d). Moreover, Fcmr−/− B-1 cells developed about twice as many 
CD138+ plasma cells compared to control B-1 cells (Fig. 6e), and the frequencies of B-1 
cell-derived IgMb secreting cells were significantly increased (Fig. 6d), while as expected, 
frequencies of IgM secreting B-2 cells (IgMa – thus wild-type) were comparable (Fig. 6f, 
right). The frequencies of IgM secreting B-1 cells (IgMb) were more than 2-fold higher in 
Fcmr−/− B-1 chimeras compared to controls, as measured by ELISPOT (Fig. 6f, left). 
Consequently, serum IgM levels generated from Fcmr−/− B-1 cells (IgMb) were substantially 
increased (Fig. 6g).
Analysis of chimeras generated by reconstituting lethally irradiated B cell deficient (μMT) 
mice with peritoneal lavage cells from Fcmr flx/flxCd19-Cre (IgHb), or controls (IgHb), as a 
source of B-1 cells, and BM cells from wild-type (IgHa) mice as a source of B-2 cells, 
yielded comparable results (Supplementary Figs. 8–9). We conclude that increased BCR 
signaling in Fcmr−/− B-1 cells directly controls natural IgM production by enhancing their 
differentiation to IgM-secreting cells in spleen and BM, likely following stimulation by 
auto-antigens.
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B-2 cell lymphocytosis in Fcmr flx/flxCd19-Cre mice
Increased IgG autoantibody production in Fcmr flx/flxCd19-Cre mice suggested that direct 
FcμR signaling also regulates the BM-derived B cell compartments. Marginal zone (MZ) B 
cells are negatively regulated by strong BCR signaling38. Consistent with findings in one 
global Fcmr−/− mouse line6, 7, 20, but not another8, we found significant reductions in 
relative frequencies of splenic MZ B cells in Fcmr flx/flxCd19-Cre mice compared to 
controls, while the relative frequencies of the FO B cell compartment appeared largely 
unaffected (Fig. 7a). However, taking total numbers of splenocytes into account, total MZ B 
cell pools were actually normal, while the numbers of splenic FO B cells were increased in 
these mice (Fig. 7a).
We also noted significant increased cell cycling and cell survival in Fcmr flx/flxCd19-Cre 
mice, specifically increased frequencies of cycling, Ki67+ FO B cells and total numbers of 
dividing B-1 and B-2 cells, as measured by BrDU incorporation (Fig. 7b–c). Fcmr
flx/flxCd19-Cre mice also yielded fewer 7AAD+, dead and dying B-1 and B-2 cells (Fig. 7d). 
The data explain that already by 3 months of age Fcmr flx/flxCd19-Cre mice showed 
significant increases in spleen cellularity and spleen enlargement (Fig. 7e,f) and by 8 months 
pronounced splenomegaly with expanded follicular compartments, as assessed histologically 
(Fig. 7g).
Discussion
This study reveals a new function for the FAIM3/FcμR in B cells, namely the control of 
surface mIgM-BCR expression and thereby the regulation of tonic BCR signaling. The 
identified extensive interaction of the FcμR with mIgM in the TGN of developing B cells 
and its inhibitory effect on mIgM accumulation on the cell surface, suggests that the FcμR 
exerts its control by regulating the transport of mIgM. The FcμR is thus identified as a 
critical regulator of B cell homeostasis.
The reported dysregulated expression of the FcμR in various human B cell malignancies 
further underscores its importance in shaping the balance between constraining and 
overshooting B cell responses to self and foreign antigens, as well as for support of B cell 
survival and rapid clonal expansion in response to pathogens. The lymphoproliferative 
disorder that develops in Fcmr flx/flxCd19-Cre mice over time is reminiscent of human cases 
of leukemic mantle cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, 
marginal zone lymphoma, and Hodgkin’s lymphoma, where a lack of FcμR expression was 
reported16. Intriguingly, the FcμR is overexpressed in other lymphomas, for example chronic 
lymphocytic leukemia, a malignancy of IgM+ B cells. The up-regulation of the FcμR could 
be an attempt by the cells to constrain chronic B cell activation and B cell expansion in these 
patients. Although we did not observe malignant B cell transformation in mice, this may be 
due to the relatively short lifespan of mice compared to humans. Worth noting, there have 
been no previous reports of lymphoproliferative disorders in the three global FcμR knockout 
mouse strains generated by others1, 7, 8. Further work is required to determine whether 
expression of the FcμR on cells other than B cells may also indirectly affect B cell 
activation.
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The FcμR-mediated control of BCR expression and signaling limits the protective capacity 
of B-1 cells by reducing natural IgM concentrations. Increased production of natural IgM 
was reported previously in global Fcmr−/− mice6, 7. Our studies demonstrated the B cell-
intrinsic nature of this regulation and identify fully differentiated CD138+ splenic B-1 cells 
as source of this increased protective IgM. Thus, while FcμR-mediated reduced tonic IgM-
BCR signaling limits B cell activation and autoantibody production by B-2 cells7, 8, it also 
constrains the protective capacity of B-1 cells.
Both, μs−/− and Fcmr−/− mice generate autoantibodies20, 39, which could indicate that sIgM-
FcμR interactions regulate autoantibody production. The underlying mechanisms of 
autoantibody-production in these two genetically altered mice, however, appear distinct. 
μs−/− show extensive alterations in B cell development, starting as early as at the pro/pre-B 
transition20, before significant FcμR expression and change the repertoire of the developing 
B-1 and B-2 cells. These changes result in increased pools of anergic and auto-antibody 
producing B-2 cells, an increased MZ B cell compartment and a near complete loss of 
peritoneal, but not splenic B-1 cells20. In contrast, B cell development appears unaffected in 
Fcmr flx/flxCd19-Cre mice, and the B-2 cell repertoire showed no major differences in 
immunoglobulin heavy-chain variable region (IGVH) usage (unpublished observations). In 
further contrast to the μs−/− mice, Fcmr flx/flxCd19-Cre mice had increased B cell pools with 
reduced, not increased, frequencies of MZ B cell, as well as expanded, rather than reduced 
B-1 cell pools. Thus, the impact on B cell homeostasis differs greatly between mice lacking 
sIgM and FcμR. This supports our conclusion that the regulation of B cell development by 
the FcμR is due mainly to its intracellular interactions with mIgM and thus control of BCR 
expression, rather than its interaction with sIgM on the B cell surface. Our data suggest a 
plausible scenario, in which mildly auto-reactive peripheral B cells that have escaped 
tolerance-induction in Fcmr flx/flxCd19-Cre mice experience chronically-enhanced tonic 
BCR-signaling via auto-antibody binding and/or by enhanced BCR auto-aggregation, due to 
enhanced IgM-BCR expression. This may result in the development of spontaneous auto-
antigen induced germinal centers, class-switch recombination and an increased production 
of IgG autoantibodies.
While enhanced B cell responsiveness in the Fcmr flx/flxCd19-Cre mice caused spontaneous 
germinal center formation and autoantibody production, exposure to influenza virus induced 
germinal centers of normal size and following normal kinetics of induction and involution 
(unpublished observations). Differential regulation of self- and foreign antigen-induced 
germinal centers is seen also in other autoimmune disease mouse models40, 41. B cells from 
Fcmr flx/flxCd19-Cre mice show spontaneous activation, despite normal expression of IgD-
BCR. Recent studies by Jumaa and colleagues42 suggested that the IgM-BCR is superior in 
responding to monovalent antigens, whereas the IgD-BCR requires polyvalent antigens. The 
data could suggest that tonic BCR-signaling is induced mainly by IgM-BCR mediated 
binding to monovalent antigens, while stimulation by highly multivalent foreign antigens/
pathogens effectively activates IgD-BCR, which is unaffected by FcμR-deficiency.
While this study focuses on FcμR-mIgM interaction in the TGN, by generating mixed BM 
irradiation chimeras between μs−/− and allotype-mismatched wild type mice, we 
distinguished the interaction of the FcμR with mIgM and sIgM ex vivo for the first time. The 
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data provide a striking image of B cells continuously uptake of sIgM, which then 
accumulates in endosomal compartments16. Given the self-reactive repertoire of natural 
IgM, this uptake may result in the continued presentation of self-antigens to T cells and 
could help with an ongoing tolerization of the T cell compartment43. In support, 
spontaneous germinal centers develop in the Fcmr flx/flxCd19-Cre mice, presumably 
requiring the breaking of tolerance in both, T cell as well as B cell compartments.
Methods
Mice
Male and female 8 – 12 week old C57BL/6 (IgHb), B6.Cg-Igha Thy1a Gpi1a/J (IgHa), and B 
cell-deficient μMT mice were obtained from The Jackson Laboratories. Fcmrflx/flx mice 
were generated by the UC Davis Mouse Biology Program MBP) using ES cells with a 
targeted deletion of exon 4 of the Fcmr, generated by the UC Davis MBP (Gene 
identification, MGI: 1916419) (https://www.komp.org/geneinfo.php?geneid=57632). Mice 
were then bred with Cd19-Cre+/− mice to generate Fcmr flx/flx Cre+ mice with a B cell-
specific deletion of the Fcmr flx/flx Cre− littermates served as controls. All mice were kept in 
specific-pathogen-free housing, in HVAC-filtered filter-top cages and are monitored for the 
absence of 17 common mouse pathogens. Mice were euthanized by overexposure to carbon 
dioxide. The Animal Use and Care Committee of the University of California, Davis, 
approved all procedures and experiments involving animals.
Mixed BM chimeras were generated by adoptively transferring equal numbers sIgM-
deficient (μs −/−, IgHa) and wild-type C57BL/6 (IgHb) BM cells into two months old 
C57BL/6 mice, lethally irradiated by exposure to a gamma-irradiation source 24 h prior to 
transfer. Chimeras were rested for at least 7 weeks before analysis.
To generate neonatal B-1 cell chimeras newborn B6.Cg IgHa mice were treated with anti-
IgMa antibodies (clone DS1.1) i.p. twice weekly for 6 weeks to temporarily deplete their B 
cells. Two δ three days after birth, pups were reconstituted with peritoneal lavage cells from 
either FcμRflx/flx Cre+ or Cre− mice (IgHb), as a source of Fcmr−/− or wild-type B-1 cells, 
respectively. Mice were analyzed no earlier than 2 months after end of anti-IgMa treatment, 
at which point all B-2 cells are host-derived (IgHa) and most B-1 cells are peritoneal cavity 
donor-derived (IgHb)25, 44, 45.
B cell isolation and in vitro B cells assays
The following B cell populations were negatively enriched by auto-MACS (Miltenyi 
Biotech) using depletion cocktails and anti-biotin Microbeads (Miltenyi Biotech) after Fc-
blocking: Spleen B cells, biotinylated conjugates against CD90.2 (30-H12), F4/80 (BM8), 
Gr-1 (RB6-8C5), and NK1.1 (PK136). Peritoneal cavity B-1 cells, CD90.2, F4/80, Gr-1, 
NK1.1, and CD23 (B3B4). FO B cells were isolated via positive selection with anti-CD23-
biotin. For proliferation assays, the cells were labeled with 0.5 μM CFSE as previously 
described20. Cells were cultured with anti-IgM (Goat anti-mouse IgM (Fab)2 (Jackson 
ImmunoResearch) 20 μg/ml medium (RPMI/10%FCS/L-glutamine/streptomycin), anti-Fas 
IgG (BD Pharmingen, Jo2) 100 ng/ml medium, or LPS (Sigma) 20 μg/ml medium in 96-well 
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round-bottom plates for 72 h at 37°C in 5% CO2. Flow cytometry analysis was done to 
identify the number of dividing cells (CFSE low) and frequencies of live cells (7AAD−).
For in vivo stimulation of B-1 cells 1.5 × 106 peritoneal cavity cells from Fcmr flx/flxCd19-
Cre or Creδ control mice (IgHb) were injected i.p into B6.Cg-IgHa mice, followed by i.p 
injection of 20 μg LPS/mouse. The sera and spleens from mice were collected 1.5 days later 
to measure IgM secretion and IgM-secreting cells by ELISA.
ELISA and ELISPOT assays
DNA-specific IgM and IgG and total IgM, IgMa, IgMb, IgG concentrations in sera were 
measured as previously described20, 46. For detection of influenza A/Puerto Rico/8/34 
binding IgM, ELISA plates were coated with 250 hemagglutinating units A/PR847. Binding 
was revealed with goat anti-mouse IgM (Southern Biotech) as previously described24. IgMδ 
and IgG-secreting cells in the spleens and BMs were enumerated by ELISPOT46.
Flow cytometry
Single-cell suspensions from spleen, BM, and peritoneal cavities were stained with anti-
CD16/32 (2.4G2) 5 μg/ml for 20 min on ice to block Fc receptors. Cells were stained with 
antibody conjugates against FcμR-biotin (MBL; clone: 4B5; in-house conjugated with 
biotin); IgDa-biotin (AMS-9.1), IgMa-biotin (DS.1), CD5-biotin (53.7–8) (in-house 
generated), PNA-biotin (Vector Laboratories, B-1075) and the following fluorochome-
conjugates: Streptavidin (SA)-Qdot 605 (Invitrogen), Fas-PE (eBioscience,15-A7), CD43-
PE (S7), CD21-FITC (7G6), CD38-FITC (90), IgD-Cy7PE (11-26C), IgDb-Cy7PE 
(AF6.122), IgMb-(FITC, PE) (AF6-78.25), IgM-(APC, Cy7APC) (331), IgMa-APC (DS.1), 
CD45R-(FITC, Cy7APC, Cy55APC) (RA3-6B2), CD19-(Cy5PE, APC) (ID3) (all in-house 
generated). Dead cells were excluded by live/dead-pacblue (Invitrogen) or 7AAD+ (BD 
Pharmingen) staining for 30 min. Staining for BrdU was done according to the 
manufacturer’s protocols using a BD Pharmingen BrdU Flow Kit. Cell cycle analysis were 
done as previously described20.
Phosphoflow: Cells were surface-stained before fixation (BD Cytofix) for 30 min on ice. 
Cells were washed and permeabilized with Perm/Wash buffer (BD) for 30 min on ice. Cells 
were washed and stained with anti-phospho-Akt-PE (BD phosphoflow, pS473) on ice for 30 
mins. For phospho-Btk, fixed and permeabilized cells were stained with anti-phospho-Btk 
PE (Y551/Y511; eBioscience) at 22°C for 30 min. For PI3K-p110 subunit and Igα (CD79a) 
staining, fixed and permeabilized cells were stained with anti-p110 Alexa Fluor 488 (Abcam 
ab202666, clone EPR5515(2)), or anti-CD79a PE (eBioscience, HM47). For PI3K-p85 
subunit staining, fixed and permeabilized cells were stained with anti-p85 (Abcam 
ab189403, 6G10), anti mouse IgG1-biotin (SouthernBiotech,1070-05), and with SA-Qdot 
605 for 30 min at each step. Flow cytometry was performed using a Fortessa (BD) equipped 
with 4-lasers and optical set-up for up to 22 parameter analysis. Flow cytometry-sorting of 
spleen and BM B cell subsets was done using a flow cytometry Aria (BD Biosciences)20.
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Fluorescence Recovery After Photobleaching (FRAP)
Schneider S2 cells were transfected with BCR IgM-GFP or IgD-GFP chimeras with and 
without co-expression of FcμR and FRAP analyzed in Ringer solution at 22°C using a 
ZEISS LSM 780 laser scanning microscope. In brief, the pixel size was adjusted to 0.44 μm, 
the image size to 512 × 512 pixel, and the pixel time to 1.58 μs. Entire cells were bleached 
per region of interest (ROI) using the 488, 561, 633, and 405 nm lasers simultaneously. GFP 
was bleached until 10% of the initial intensity was reached (duration varied from 1–5s). In 
total, 171 image series containing about 12–15 ROI were recorded with the 488/514 nm 
Argon laser. Each image series included ten pre-bleach (every 5s) and 161 post bleach 
images (every 5–20s) in a 16-bit format. Images were taken until GFP recovery plateaued. 
Vertical drift was not observed during the measurement because S2 cells adhere to the plate. 
Values for background analysis were taken from non-bleached and bleached areas 
containing no cells. The obtained recovery traces (with time set to 0 for the first frame post 
bleach) were corrected for the photomultiplier (PMT) error, background and bleaching 
during recovery, and normalized to the pre-bleach fluorescence intensity defined as 100%. 
The mobile fraction (Mf) was calculated using the published equation48, 49 and the 
photobleaching correction50:
Where Fprecell is the whole cell pre-bleach intensity, Fpre is the bleach ROI pre-bleach 
intensity, F∞cell is the asymptote of fluorescence recovery of the whole cell, and Fbackground 
is the mean background intensity that includes PMT correction. F∞ is the bleach ROI 
asymptote, and F0 is the bleach ROI immediate post bleach intensity. Curve fitting and 
asymptote calculation was performed in GraphPad Prism (nonlinear regression analysis).
The half-time of recovery (t1/2) was determined by solving the following equation49: 
. Where F0 is the bleach ROI immediate post bleach 
intensity, F∞ is the asymptote of the bleach ROI fluorescence recovery, t is the time for each 
ROI intensity value in seconds, and t1/2 is the time required for the bleach ROI to recover to 
50% of the asymptote. For one experiment and condition 10 data sets with 9–12 cells of 
each transfection were analyzed, normalized, and averaged for M(f) as well as half-time 
recovery. In total, two independent FRAP experiments were performed.
In vitro sIgM-binding assay
The in vitro sIgM binding assay was performed as previously described20. Briefly, cells 
were incubated with sIgM-biotin (SouthernBiotech, Clone 11E10) for 30 minutes at 4°C. 
Binding was revealed by staining with Streptavidin-Qdot605.
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In vitro assay of FcμR and membrane IgM interaction
FcμR cDNA was amplified and cloned into pBluescript from splenic B cells of C57BL/6 
mice with primers Fcmr-29s (5′-AAGGCTCCCAGGTGATCGG-3′) and Fcmr-1491a (5′-
GGGGTGAAAAATTAGCCTGTAATTG-3′). The restriction sites (EcoRI and SacI) were 
added using primers 5′-TGCATGCAGAATTCCCATGGACTTTTGGCT T-3′ and 5′-
TGCATGCAGAGGTCACTCATTGGCATGAAGA-3′. Fcmr was inserted in pRmHa-3 
plasmid at the EcoRI and SacI sites. FcμR construct was co-expressed with GFP-μmHc and 
mcherry-δmHc constructs in Drosophila S2 cells, as previously outlined28 and stained with 
anti IgM-V450 (BD) or anti IgD-Alexa 647 (Abcam).
Proximity-Ligation Assay
Proximity-ligation assay (PLA) was performed as previously described27. In brief: PLA-
probes against specific targets, the following unlabeled Abs were used: anti-IgM (BD 
Biosciences, 1B4B1), anti-FcμR (Novus Biologicals, pc). Fab fragments were prepared with 
Pierce Fab Micro preparation kit (Thermo Scientific) using immobilized papain according to 
the manufacturer’s protocol. After desalting (Zeba spin desalting columns, Thermo 
Scientific), the Fab fragments were coupled with PLA Probemaker Plus or Minus 
oligonucleotides (Sigma-Aldrich) to generate Fab-PLA probes. Naive B cells were enriched 
by MACS depletion using anti-CD43 MicroBeads (Miltyeni Biotec) according to the 
manufacturer’s protocol. BM B cells were negatively selected by auto-MACS (Milteny 
Biotech) using anti CD43-biotin, anti CD25-biotin, and anti IgD-biotin depletion and 
streptavidin Microbeads (Miltenyi Biotech) after Fc-blocking. The enriched B cells were 
rested overnight in complete RPMI 1640 medium. For in situ PLA, B cells were settled on 
polytetrafluoroethylene slides (Thermo Fisher Scientific) for 30 min at 37 °C. BCR. 
Fixation, permeabilization, and PLA reactions were conducted according to the previously 
mentioned protocol27. Surface costaining for GM-1 was performed with cholera-toxin suB-
FITC (Sigma-Aldrich). Intracellular Golgi was stained with Golgiδ lectin GSII Alexa-488 
(Molecular Probes) according to manufacturer’s protocol. Resulting samples were directly 
mounted on slides with DAPI Fluoromount-G (SouthernBiotech) to visualize the PLA 
signals in relationship to the nuclei. Microscopic images were acquired with a Zeiss 780 
Meta confocal microscope (Carl Zeiss). For each experiment a minimum of 250 immature B 
and 750 B-2 cells from several images were analyzed (ImageJ). Raw data were exported to 
Prism software (GraphPad Software). For each sample, the mean PLA signal count per cell 
was calculated from the corresponding images and the statistical significance with Student’s 
t-test. Co-localization of confocal images (Pearson’s correlation (total R) and Manders split 
coefficients) of TGN, 488 nm laser (channel1), and PLA, 561 nm laser (channel 2) were 
analyzed for 40 cells with FIJI (ImageJ).
Histology
Spleens were fixed in neutral buffered formalin, embedded in paraffin, sectioned (4μm 
thickness), and stained with H&E.
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Immunofluorescence confocal microscopy
Splenic IgHa IgM−/− B cells were negatively enriched from mixed IgM−/− and wild-type 
chimeras by auto-MACS (IgDb, CD90.2, F4/80, Gr-1, NK1.1 biotin). After fixing with BD 
cytoperm/cytofix buffer, IgM−/− B cells were incubated with IgMb biotin (clone AF6-78.25), 
IgMa Alexa 488 (clone DS.1) followed by fluorescent SA Alexa 555 (Life Technologies; 
Ref. S21381) each for 30 min. For FcμR staining, the cells were stained with FcμR Abs 
(MBL, clone 4B5, IgG2a) and then with anti-rat IgG2a Alexa 647 (Abcam, clone 2A 8F4, 
Ref. ab172333). mIgM and sIgM were imaged with the same system in STED mode, 
depletion was accomplished with a 592nm laser for Alexa 488 and a 660nm laser for Alexa 
555.
Late pre-B cells and immature B cells (CD45R+CD43−IgD−) were sorted by flow cytometry 
from C57BL/6 BM cells, fixed with BD cytoperm/cytofix buffer and washed with Perm/
Wash buffer (BD). Cells were stained with FcμR-biotin (MBL, clone 4B5) and trans-Golgi 
network antibody TGN38 (BD, Cat. 610898, 2/TGN38) at 22°C for 30 mins. After washing, 
fluorescent SA-Alexa 555 (Life Technologies; Ref. S21381) and IgM Alexa 488 (clone 331) 
were added and incubated for 30 min followed by anti-mouse IgG1 Alexa 647 (Biolegend, 
Cat. 406617) to visualize TGN-38. The cells were washed 3 times with PBS. Cells were 
transferred in 20 μl PBS to coverslips (Corning; Cat. 2850-22), and mounted with Prolong 
Diamond Antifade Mountant (Life Technologies, Ref. P36961). Images were acquired on a 
Leica SP8 TCS STED 3X microscope system with an HC PL APO 100X/1.4 NA STED 
objective either in confocal (IgM and TGN 38) or STED (FcμR) mode. Fluorophores were 
excited with a white light laser and a 660 nm depletion laser was used for STED imaging.
qRT-PCR
Total RNA from different B cell subsets was isolated with RNeasy (Qiagen) and stored at 
−80C in RNA storage buffer (Ambion) until use. Complementary DNA was prepared as 
previously described20. Rag1, Aicda, Cdkn1b, Bcl2l11 and membrane IgM mRNA 
expression were measured as described previously29, 51. Fcmr expression was measured 
using a commercial primer/probe set (Mm01302388_m1; Applied Biosystems). Quantitative 
PCR was performed using a 7900HT Fas Real-Time PCR system (Applied Biosystems) with 
following cycles: 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15s and 60°C 
for 1 min. Relative expression was normalized to Gapdh (Mm.P.T.39a.1; IDT).
Influenza virus infection and viral load determination
Fcmr flx/flxCd19-Cre and control mice were anesthetized with isoflurane and infected 
intranasally with 20 PFU influenza A/Puerto Rico/8/34 (A/PR8; H1N1) per mouse in 40 μl 
PBS. Lungs were harvested 24 h after infection and RNA was extracted from lung 
homogenates (gentleMACS, Miltenyi Biotec) using a QIAamp Viral RNA mini kit (Qiagen). 
Viral and cDNA was prepared as described20. A/PR8 virus loads were measured using 
primer/probe sets for a conserved portion of the viral matrix protein AM151 (5′-
CATGGAATGGCTAAAGACAAGACC-3′), AM397 (5′-
AAGTGCACCAGCAGAATAACTGAG-3′), AM245 
(5′-6FAMCTGCAGCGTAGACGCTTTGTCCAA AATGTAMRA-3′). Quantitative PCR 
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was performed using Standard TaqMan Cycling conditions as described above. 10-fold 
serial dilution of cDNA from stock A/PR8 virus was used to generate a standard curve.
Statistical Analysis
All data are shown as mean ± standard deviation (SD). Statistical analysis of data in Fig. 2i,j, 
and Fig.3h was done using the Mann-Whitney test. Statistical analysis of Fig. 3g was done 
using Wilcoxon matched-pairs signed rank test. For the other data, statistical analysis was 
done using paired or unpaired two-tailed Student’s t test. P < 0.05 was considered to show 
significantly differences, *p<0.05, **p<0.005, ***p<0.0005.
Data availability
The data that support the findings of this study are available from the corresponding author 
upon request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported by NIH AI51354, NIH AI85568, U19AI109962 (N.B), the UC Davis Graduate Group in 
Immunology, a Vietnamese Education Fellowship to T.T.T.N., a UC Davis Chancellor’s Fellowship to N.B. and by 
the Excellence Initiative of the German Federal and State Governments (EXC 294), by ERC-grant 322972, by the 
DFG through TRR130 and project 111026 of the German Cancer Aid (M.R). We thank Ms. Spinner (California 
National Primate Research Center, UC Davis) for help with flow cytometry, Mr. Treister for FlowJo software, Dr. 
Pohlmeyer for sharing flow cytometry data, and Dr. Cavallari for help with image analysis. We thank Dr. Kubagawa 
for providing bone marrows from global Fcmr−/− mice. Special thanks to the UC Davis Mouse Biology Program 
for generating the Fcmr flx/flxCd19-Cre mice.
References
1. Nguyen XH, et al. Toso regulates the balance between apoptotic and nonapoptotic death receptor 
signaling by facilitating RIP1 ubiquitination. Blood. 2011; 118:598–608. [PubMed: 21613257] 
2. Nguyen XH, et al. Antiapoptotic function of Toso (Faim3) in death receptor signaling. Blood. 2012; 
119:1790–1791. [PubMed: 22448402] 
3. Hitoshi Y, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. 
Immunity. 1998; 8:461–471. [PubMed: 9586636] 
4. Kubagawa H, et al. Identity of the elusive IgM Fc receptor (FcmuR) in humans. The Journal of 
experimental medicine. 2009; 206:2779–2793. [PubMed: 19858324] 
5. Ouchida R, Mori H, Ohno H, Wang JY. FcmuR (Toso/Faim3) is not an inhibitor of Fas-mediated 
cell death in mouse T and B cells. Blood. 2013; 121:2368–2370. [PubMed: 23520334] 
6. Ouchida R, et al. Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, and 
humoral immune responses. Proceedings of the National Academy of Sciences of the United States 
of America. 2012; 109:E2699–2706. [PubMed: 22988094] 
7. Honjo K, et al. Altered Ig levels and antibody responses in mice deficient for the Fc receptor for 
IgM (FcmuR). Proceedings of the National Academy of Sciences of the United States of America. 
2012; 109:15882–15887. [PubMed: 22984178] 
8. Choi SC, et al. Mouse IgM Fc receptor, FCMR, promotes B cell development and modulates 
antigen-driven immune responses. Journal of immunology. 2013; 190:987–996.
9. Lang KS, et al. Involvement of Toso in activation of monocytes, macrophages, and granulocytes. 
Proceedings of the National Academy of Sciences of the United States of America. 2013; 
110:2593–2598. [PubMed: 23359703] 
Nguyen et al. Page 16
Nat Immunol. Author manuscript; available in PMC 2017 July 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
10. Brenner D, et al. Toso controls encephalitogenic immune responses by dendritic cells and 
regulatory T cells. Proceedings of the National Academy of Sciences of the United States of 
America. 2014; 111:1060–1065. [PubMed: 24398517] 
11. Lang PA, et al. Toso regulates differentiation and activation of inflammatory dendritic cells during 
persistence-prone virus infection. Cell death and differentiation. 2015; 22:164–173. [PubMed: 
25257173] 
12. Ouchida R, et al. FcmuR Interacts and Cooperates with the B Cell Receptor To Promote B Cell 
Survival. Journal of immunology. 2015; 194:3096–3101.
13. Baeuerle PA, Huttner WB. Tyrosine sulfation is a trans-Golgi-specific protein modification. The 
Journal of cell biology. 1987; 105:2655–2664. [PubMed: 3121635] 
14. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by 
inducible gene targeting results in rapid cell death. Cell. 1997; 90:1073–1083. [PubMed: 9323135] 
15. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nature reviews 
Immunology. 2002; 2:945–956.
16. Vire B, David A, Wiestner A. TOSO, the Fcmicro receptor, is highly expressed on chronic 
lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is 
downregulated in response to TLR activation. Journal of immunology. 2011; 187:4040–4050.
17. Li FJ, et al. Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor 
(FcmuR) in patients with chronic lymphocytic leukemia. Blood. 2011; 118:4902–4909. [PubMed: 
21908424] 
18. Shima H, et al. Identification of TOSO/FAIM3 as an Fc receptor for IgM. International 
immunology. 2010; 22:149–156. [PubMed: 20042454] 
19. Thorens B, Schulz MF, Vassalli P. Bone marrow pre-B lymphocytes synthesize immunoglobulin 
mu chains of membrane type with different properties and intracellular pathways. The EMBO 
journal. 1985; 4:361–368. [PubMed: 3926483] 
20. Nguyen TT, Elsner RA, Baumgarth N. Natural IgM Prevents Autoimmunity by Enforcing B Cell 
Central Tolerance Induction. Journal of immunology. 2015; 194:1489–1502.
21. Schermelleh L, Heintzmann R, Leonhardt H. A guide to super-resolution fluorescence microscopy. 
The Journal of cell biology. 2010; 190:165–175. [PubMed: 20643879] 
22. Boes M, et al. Enhanced B-1 cell development, but impaired IgG antibody responses in mice 
deficient in secreted IgM. Journal of immunology. 1998; 160:4776–4787.
23. Sieckmann DG, Stall AM, Subbarao B. A mouse monoclonal antibody specific for an allotypic 
determinant of the Igha allele of murine IgM: genetic and functional analysis of Igh-6a epitopes 
using anti-IgM monoclonal antibodies. Hybridoma. 1991; 10:121–135. [PubMed: 1709612] 
24. Choi YS, Baumgarth N. Dual role for B-1a cells in immunity to influenza virus infection. The 
Journal of experimental medicine. 2008; 205:3053–3064. [PubMed: 19075288] 
25. Lalor PA, Herzenberg LA, Adams S, Stall AM. Feedback regulation of murine Ly-1 B cell 
development. European journal of immunology. 1989; 19:507–513. [PubMed: 2785046] 
26. Andersson J, Lafleur L, Melchers. IgM in bone marrow-derived lymphocytes. Synthesis, surface 
deposition, turnover and carbohydrate composition in unstimulated mouse B cells. European 
journal of immunology. 1974; 4:170–180. [PubMed: 4604559] 
27. Klasener K, Maity PC, Hobeika E, Yang J, Reth M. B cell activation involves nanoscale receptor 
reorganizations and inside-out signaling by Syk. eLife. 2014; 3:e02069. [PubMed: 24963139] 
28. Yang J, Reth M. Drosophila S2 Schneider cells: a useful tool for rebuilding and redesigning 
approaches in synthetic biology. Methods in molecular biology. 2012; 813:331–341. [PubMed: 
22083752] 
29. Srinivasan L, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009; 139:573–
586. [PubMed: 19879843] 
30. Werner M, Hobeika E, Jumaa H. Role of PI3K in the generation and survival of B cells. 
Immunological reviews. 2010; 237:55–71. [PubMed: 20727029] 
31. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? 
Trends in cell biology. 2003; 13:65–70. [PubMed: 12559756] 
Nguyen et al. Page 17
Nat Immunol. Author manuscript; available in PMC 2017 July 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
32. Gogada R, et al. Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent 
mechanism, functions as a prosurvival molecule in cancer. The Journal of biological chemistry. 
2013; 288:368–381. [PubMed: 23152504] 
33. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. 
Nature reviews Drug discovery. 2009; 8:627–644. [PubMed: 19644473] 
34. Hayakawa K, et al. Positive selection of natural autoreactive B cells. Science. 1999; 285:113–116. 
[PubMed: 10390361] 
35. Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annual 
review of immunology. 2002; 20:253–300.
36. Baumgarth N, et al. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant 
components of the protective response to influenza virus infection. The Journal of experimental 
medicine. 2000; 192:271–280. [PubMed: 10899913] 
37. Ochsenbein AF, et al. Control of early viral and bacterial distribution and disease by natural 
antibodies. Science. 1999; 286:2156–2159. [PubMed: 10591647] 
38. Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nature 
reviews Immunology. 2009; 9:767–777.
39. Boes M, et al. Accelerated development of IgG autoantibodies and autoimmune disease in the 
absence of secreted IgM. Proceedings of the National Academy of Sciences of the United States of 
America. 2000; 97:1184–1189. [PubMed: 10655505] 
40. Jackson SW, et al. B cell IFN-gamma receptor signaling promotes autoimmune germinal centers 
via cell-intrinsic induction of BCL-6. The Journal of experimental medicine. 2016; 213:733–750. 
[PubMed: 27069113] 
41. Rahman MJ, et al. Despite Increased Type 1 IFN, Autoimmune Nonobese Diabetic Mice Display 
Impaired Dendritic Cell Response to CpG and Decreased Nuclear Localization of IFN-Activated 
STAT1. Journal of immunology. 2016; 196:2031–2040.
42. Ubelhart R, et al. Responsiveness of B cells is regulated by the hinge region of IgD. Nature 
immunology. 2015; 16:534–543. [PubMed: 25848865] 
43. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science. 1992; 258:1156–
1159. [PubMed: 1439825] 
44. Baumgarth N, et al. Innate and acquired humoral immunities to influenza virus are mediated by 
distinct arms of the immune system. Proceedings of the National Academy of Sciences of the 
United States of America. 1999; 96:2250–2255. [PubMed: 10051627] 
45. Stall AM, Wells SM, Lam KP. B-1 cells: unique origins and functions. Seminars in immunology. 
1996; 8:45–59. [PubMed: 8850298] 
46. Choi YS, Dieter JA, Rothaeusler K, Luo Z, Baumgarth N. B-1 cells in the bone marrow are a 
significant source of natural IgM. European journal of immunology. 2012; 42:120–129. [PubMed: 
22009734] 
47. Doucett VP, et al. Enumeration and characterization of virus-specific B cells by multicolor flow 
cytometry. J Immunol Methods. 2005; 303:40–52. [PubMed: 16045923] 
48. Snapp EL, Altan N, Lippincott-Schwartz J. Measuring protein mobility by photobleaching GFP 
chimeras in living cells. Current protocols in cell biology/editorial board, Juan S. Bonifacino ... [et 
al.]. 2003; Chapter 21(Unit 21):21.
49. Feder TJ, Brust-Mascher I, Slattery JP, Baird B, Webb WW. Constrained diffusion or immobile 
fraction on cell surfaces: a new interpretation. Biophysical journal. 1996; 70:2767–2773. 
[PubMed: 8744314] 
50. Lippincott-Schwartz J, et al. Monitoring the dynamics and mobility of membrane proteins tagged 
with green fluorescent protein. Methods in cell biology. 1999; 58:261–281. [PubMed: 9891386] 
51. Reimold AM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 
2001; 412:300–307. [PubMed: 11460154] 
Nguyen et al. Page 18
Nat Immunol. Author manuscript; available in PMC 2017 July 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. The FcμR is expressed by various cell subsets
(a) Fcmr mRNA expressions in different B cell subsets in spleen and peritoneal cavities 
(perc): marginal zone (MZ), follicular (FO), spleen B-1, and perc B-1 cells. Each symbol 
represents values from one mouse (n=3 mice). (b) Surface FcμR expression in different B 
cell subsets in spleen, perc, and inguinal lymph node (pLN) (n=6 mice) (c) Fcmr mRNA 
expression by different B cell developmental stages (n = 4–10 samples/group, each sample 
was sorted from BM of 2 mice). (d) Surface FcμR expression by pro- and early pre- B cells, 
late pre-, immature and mature B cells (n=6 mice). (e) Confocal microscopy of immature B 
cells stained with FcμR (green) and TGN-38 (blue). White bars indicate 2 μm scale bars. (f) 
Relative expression of Fcmr mRNA of purified Fcmr flx/flxCd19-Cre and control B cells 
(n=6 mice/group). Data are combined from 3 independent experiments (c) or are 
representative of at least two independent experiments (a–b, d–f) (mean ± SD in a–d, f). 
*p<0.05, **p<0.005, ***p<0.0005 by unpaired two-tailed Student’s t-test.
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Figure 2. IgM FcμR interaction occurs with both secreted and membrane IgM
(a) Shown are histogram plots of splenic B cells from control and Fcmr flx/flxCd19-Cre mice 
incubated or not with biotinylated IgM and stained with streptavidin-PE. (b) Splenocytes 
from Fcmr flx/flxCd19-Cre and control mice (IgHb) were i.v transferred into C6.IgHa mice 
(n=3 mice/group). Shown are 5% contour plots with outliers gated on live CD19+ B cells, 
identifying transferred B cells as IgDa− and IgDb+. (c) Overlay histograms comparing IgMa 
(in vivo sIgM binding) and IgMb (membrane IgM) expression of transferred B cells (IgDa− 
IgDb+) from Fcmr flx/flxCd19-Cre and control mice 3 days after transfer. Graph summarizes 
mean fluorescence intensities ± SD of IgMa and IgMb staining of transferred B cells. (d) 
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Fold-difference in MFI from IgMb (mIgM) of Fcmr flx/flxCd19-Cre B cells compared to 
controls. (e,f) Follicular B cells unable to secrete IgM (μs −/−) were isolated from mixed BM 
μs−/− (IgMa) and WT (IgMb) chimeras. (e) STED microscopy of μs−/− B cells stained for 
sIgM (IgMb-green) and mIgM (IgMa-red). (f) Confocal microscopy of μs −/− follicular B 
cells stained for FcμR (green), mIgM (IgMa, red), and sIgM (IgMb, blue). White arrows 
identify co-localization of FcμR with mIgM or sIgM. (g) STED microscopy of immature B 
cells stained for FcμR (green) and IgM (red). (h) Confocal microscopy of immature B cells 
stained with FcμR (green), IgM (red) and TGN-38 (blue). Scale bars 2μm. (i–j) Quantified 
box-and-whisker-plots (min, max, median, quartiles) and microscopic representation of 
Proximal ligation assay (PLA) of GFP-sorted (i) BM immature (n=250 cells) and (j) splenic 
mature B cells (n=750 cells) treated with or without saponin prior to PLA, as indicated. Red 
indicates FcμR-IgM interaction. Green shows staining of Golgi network using labeled lectin-
GSII staining (J-top, K-top) or GM-1 staining indicating the cell membrane, using labeled 
cholera-toxin subunit B (J-bottom, K-bottom). DAPI stained nuclei presented in blue. Scale 
bar 2μm. Data are representative of at least two independent experiments. *p<0.05, 
**p<0.005, ***p<0.0005 by unpaired two-tailed Student’s t-test (a–c) or Mann-Whitney test 
(i–j).
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Figure 3. FcμR-mIgM interactions constrain BCR surface expression
(a) Overlay histogram flow cytometry plots comparing total surface IgM staining 
(membrane plus secreted IgM binding), on splenic CD19+ B cells from Fcmr flx/flxCd19-Cre 
and control mice. (b) Overlay histograms comparing IgM (membrane IgM) expression on B 
cells (IgDa− IgDb+) from Fcmr flx/flxCd19-Cre and control mice 3 days after transfer into 
IgHa mice. (c) Mean fluorescence intensities ± SD of staining for Igα (CD79a) in total 
spleen B cells from Fcmr flx/flxCd19-Cre and control mice (n=4 mice/group). (d) Mean 
relative expression of membrane IgM (BCR) mRNA ± SD of purified Fcmr flx/flxCd19-Cre 
and control B cells (n=4 mice/group). Data are representative of at least two independent 
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experiments. (e) Model of the GFP-μm heavy chain (GFP-μmHc) and the assembled 
chimeric IgM-BCR containing the CD79a and CD79b signaling subunits, the mcherry-
δmHc and the assembled chimeric IgD-BCR expressed in S2 cells. (f) Shown are flow 
cytometry histogram plots of Drosophila S2 cells stained for IgM or IgD. The cells 
expressed GFP, GFP-μmHc, mcherry-δmHc, IgM-BCR ± FcμR, IgD-BCR ± FcμR. (g) Box-
and-whisker-plots (min, max, median, quartiles) summarize MFI of surface IgM (left) and 
surface IgD (right) expression by S2 cells after transfection. (h,i) Shown are IgM (left) and 
IgD (right) re-expression by transfected S2 cells after photobleaching (FRAP) (n=50 cells). 
The cells expressed the IgM-BCR as GFP-coupled chimera described in (e) and the IgD-
BCR GFP-chimera with or without the FcμR. (h) Mean ratios of fluorescence staining of the 
mobile fraction (Mf) ± SD. (i) Box-and-whisker-plots (min, max, median, quartiles) 
summarize the half-time recovery. Data are representative of at least two independent 
experiments (a–d, h–i). Data are combined from five independent experiments (f–g). n.s. not 
significantly different, *p<0.05, **p<0.005, ***p<0.0005 by unpaired two-tailed Student’s 
t-test (c,d,i), Wilcoxon matched-pairs signed rank test (g), or Mann-Whitney test (h, 
***p<0.0001 for IgM-BCR, and n.s for IgD-BCR).
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Figure 4. Enhanced tonic BCR signaling in Fcmr−/− B cells
(a–c) MFI ± SD of ex vivo staining for expression of (a) PI3K-p85 and (b) PI3K-p110 by 
flow cytometry. (c) Overlay histograms (left) and graph summarizing MFI ± SD of phospho 
(p)Akt expression by total B cells from Fcmr flx/flxCd19-Cre mice and Fcmr flx/flx Cre-
negative controls (right). (d) pAkt expression levels in total spleen B cells, FO B (B-2) and 
B-1 cells. (e) Overlay histograms of phospho (p)Btk expression by total B cells from 
indicated mice (left). Graph summarizing MFI ± SD of phospho (p)Btk expression. (f) pBtk 
expression in total spleen B cells, FO B (B-2) and B-1 cells from Fcmr flx/flxCd19-Cre and 
control mice (n=3–4 mice/group). (g) 5% contour plots with outliers gated on lived splenic 
B-1 cells from Fcmr flx/flxCd19-Cre and control mice, showing the correlation of surface 
IgM and pAkt expression. (h) mRNA expression levels of FOXO target genes Rag1, Aicda, 
Cdkn1b, and Bcl2l11 in Fcmr flx/flxCd19-Cre and control B cells after normalization to 
Gapdh (n=4 mice/group). (i) FO B cells isolated from spleens of Fcmr flx/flxCd19-Cre and 
control mice labeled with CFSE and stimulated with anti-IgM for 72h. Numbers are rounds 
of cell divisions. (j) pAkt expression levels (ΔMFI= mean fluorescent intensity (MFI) – MFI 
fluorescence minus one (FMO) control) after 72h culture with/without anti-IgM. (k) FO B-2 
cells isolated from Fcmr flx/flxCd19-Cre and control spleens stimulated as indicated for 72h. 
Frequencies of live cells as determined by 7-AAD staining. (l) Frequencies of live (7-AAD−) 
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B-1 cells isolated from Fcmr flx/flxCd19-Cre and control spleens and stimulated as indicated 
for 48h (n=3 samples pooled from 2 mice (k–l)). Each data set is representative of at least 
two independent experiments (mean ± SD in a–f, h, j–l). *p<0.05, **p<0.005 by unpaired 
two-tailed Student’s t-test.
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Figure 5. Increased influenza-protective natural IgM and autoantibody production in Fcmr
flx/flxCd19-Cre mice
Concentrations of (a) IgM, (b) IgA, (c) IgG in Fcmr flx/flxCd19-Cre and control sera from 3 
months old mice (n=10–18 mice/group). (d) Frequencies of IgM and (e) IgG secreting cells 
in spleens and BMs of these mice (n=4 mice/group). (f) Relative amounts of IgM and (g) 
IgG anti-dsDNA and relative amounts of anti-dsDNA/mg Ig per μg total Ig in Fcmr
flx/flxCd19-Cre and control sera (n=10–12 mice/group). (h) Overlay histograms of Fas 
expression by B cells from indicated mice (left). Graph summarizing results (right) (n=2 
mice/group). (i) 5% contour plots with outliners gated on live CD19+ B cells. Gate and 
numbers identify CD38low PNA+ germinal center (GC) B cells. Graphs summarize 
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frequencies ± SD GC B cells of total cells in Fcmr flx/flxCd19-Cre and control spleens (n=4–
5 mice/group). (j) Relative amounts influenza A/Puerto Rico/8/34-binding IgM in sera from 
naïve Fcmr flx/flxCd19-Cre and control mice (n=15–18 mice/group). (k) Relative amounts of 
influenza A/PR8-binding and (l) total IgM in sera of Fcmr flx/flxCd19-Cre, and control mice 
one day after A/PR8 infection (n=8, 14 mice/group). Data are representative of at least two 
independent experiments. (m) Lung viral loads at 1 day after A/PR8 infection. For Figure k, 
l and m data are combined from three independent experiments (mean ± SD in a–m). 
*p<0.05, **p<0.005, ***p<0.0005 by unpaired two-tailed Student’s t-test.
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Figure 6. B-1 cells are responsible for increased natural IgM secretion in Fcmr flx/flxCd19-Cre 
mice
(a) 5% contour plots with outliers gated for live CD19+ spleen B cells from control and 
Fcmr flx/flxCd19-Cre mice. B-1 cells were identified as: CD43+ IgMhi CD19hi and CD5+/− 
(B-1a/B-1b). Graph summarizes numbers of B-1 cells, including B-1a and B-1b cells in 
spleen, (b) peritoneal cavity and (c) BM (n=4 mice/group). (d–g) Generation of chimeras 
with Fcmr−/− B-1 (IgHb) and wild-type B-2 (IgHa) cells and controls (n=4 mice/group). (d) 
(left) 5% contour plots with outliers gated for lived CD19+ B cells from peritoneal cavities 
and spleens. For BM, cells were pre-gated for B-1 cells (CD19+ IgM+ CD43+). The 
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transferred B-1 cells were identified as IgMb+ IgMa−. Graph provides summary of IgMb B-1 
cell frequencies in indicated tissues. (e) 5% contour plots with outliers gated on IgMb+ B-1 
cells in spleen. Gates and numbers identify frequencies of CD138+ of IgMb+ B-1 cells. 
FMO, fluorescence minus one control. (f) Graphs summarize the frequencies of IgMb 
secreting B-1 (left) and IgMa secreting B-2 cells (right) in spleen, and BMs. (g) Serum IgMb 
levels in the chimera. Data are representative of at least two independent experiments (a–c) 
(mean ± SD in a–d, f–g). *p<0.05, **p<0.005, ***p<0.0005 by unpaired two-tailed 
Student’s t-test.
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Figure 7. Increased B cell turnover and cell survival of B cells result in B cell lymphocytosis
(a) 5% contour plots with outliers of representative spleen samples (n=4 mice/group) from 
Fcmr flx/flxCd19-Cre and control mice analyzed by flow cytometry after gating on live 
CD19+ B cells. Identified subsets: CD21hiCD23− marginal zone B cells (MZ); 
CD21intCD23+ follicular B cells (FO) (left). Graph summarizes frequencies (middle) and 
numbers (right) of MZ and FO in Fcmr flx/flxCd19-Cre and control spleens. (b–c) Cell cycle/
turnover analysis of CD19+ live spleen B cells from Fcmr flx/flxCd19-Cre and control mice 
(n=4 mice/group). (b) 5% contour plots with outliers of live CD19+ B cells from indicated 
mice, identifying cell cycle stages by Ki67 and 7-AAD staining (G0: Ki67− 7AAD−, G1: 
Ki67+ 7AAD−; G2/S/M: Ki67+ 7AAD+). Graph summarizes frequencies (n = 4 mice/group). 
(c) B-2 and B-1 cell turnover was determined by flow cytometry 24h after i.p. injection of 
BrdU. Shown are frequencies of BrdU+ cells (n=4 mice/group). (d) 5% contour plots with 
outliers gated on 7AAD+ (dead cells) among splenic live CD19+ CD43+ IgMhi IgDlo B-1 
cells (left). Shown are frequencies of 7AAD+ cells (n=4 mice/group; right). (e) Total spleen 
(left) and B cell counts (right) of indicated mice (n=8 mice/group). (f) Photo of 
representative spleens from 3-months old control and Fcmr flx/flxCd19-Cre mice. (g) H&E 
staining of spleens from 8-months old C57BL/6 and Fcmr flx/flxCd19-Cre mice. 2X scale bar 
is 500μm, 10X scale bar is 100μm. Data are representative of at least two independent 
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experiments. Data are combined from two independent experiments (f) (mean ± SD in a–e). 
*p<0.05, **p<0.005, ***p<0.0005 by unpaired two-tailed Student’s t-test.
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